Please login to the form below

Not currently logged in
Email:
Password:

NDA Group appoints new vice president

Dr Werner Van den Eynde will also lead its advisory board

Regulatory affairs consultancy group NDA has appointed Dr Werner Van den Eynde as its new vice president to head up its advisory board providing strategic advice to pharmaceutical clients during its drug development life cycle.

Eynde comes to the Swiss group with international pharmaceutical experience, having held senior positions for the likes of GE Healthcare, Abbott and Solvay Pharmaceuticals.

His new role will see him manage strategy operations and development of the NDA advisory board, including business development, sales, marketing and service development.

He said: “NDA is the perfect platform for anyone who wants to have a positive impact on drug development across the world and the excellent reputation of the NDA advisory board is wide spread.

“Building on an almost twenty year tradition of unbiased advice to drug developing companies, I’m very motivated to continue the NDA success story and expand the advisory board to meet the future demands that science, technology and the regulatory environment put on companies developing therapies for patients.”

Eynde joins the group from Chemo – Exeltis where he was head of R&D, regulatory affairs and pharmacovigilance.

Johan Stromquist, chief executive officer, NDA Group, said: “ With his [Eynde] experience in drug development, following the process from many perspectives, he will be able to add tremendous value to clients in all stages of development, as well as create tailored teams and services of great benefit to the drug development industry.”

6th September 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics